SGLT2 inhibitors × quality of life & behaviour

TrialNutrition & diabetes2021

Dapagliflozin increases the lean-to total mass ratio in type 2 diabetes mellitus.

Vaneza Lira W Wolf et al.PubMed ↗Full text ↗Publisher ↗

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower quality of life & behaviour

−84%−95% to −55%

Bigger than almost all on the map

As reported

OR 0.16, 95% CI 0.05–0.45

Correlation, not cause

Went with lower quality of life & behaviour

−87%−97% to −43%

Bigger than almost all on the map

As reported

OR 0.13, 95% CI 0.03–0.57

Two numbers in the abstract

the abstract, start to end

in the lean-to total mass ratio [OR: 0.16 (95% CI: 0.05 to 0.45); p < 0.001] even after adjustment for baseline lean-to total mass ratio, waist circumference, HOMAIR, HbA1c, mean of the two hands handgrip strength and gait speed [OR: 0.13 (95% CI: 0.03-0.57);

← favours treatmentfavours comparator →
could be chance
Quality of life & behaviour
OR 0.160.05–0.45
Quality of life & behaviour
OR 0.130.03–0.57
SGLT2 inhibitorsQuality of life & behaviour
1 / 3

10 papers cite it

2021
2022
2023
2024
2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 34120150